Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
In summary, there is a high medical need for patients suffering from recurrent/progressive
PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the
treatment of these patients.